Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the White Matter Study Group

Journal of Magnetic Resonance Imaging

Volumn 21, Issue 6, 2005, Pages 669-675

  Filippi, Massimo ^a   Falini, Andrea ^a   Arnold, Douglas L ^b   Fazekas, Franz ^c   Gonen, Oded ^d   Simon, Jack H ^e   Dousset, Vincent ^f   Savoiardo, Mario ^g   Wolinsky, Jerry S ^h  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF GRAZ   (Austria)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g DEPARTMENT OF NEUROSURGERY   (Italy)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Axonal loss; Demyelination; Inflammation; Magnetic resonance imaging; Multiple sclerosis; White matter disorders diagnostic workup

Indexed keywords

N ACETYLASPARTIC ACID;

AXONAL INJURY; BLOOD BRAIN BARRIER; BRAIN DISEASE; CLINICAL PROTOCOL; CONFERENCE PAPER; DEMYELINATION; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE DIAGNOSIS; TECHNIQUE; VOLUMETRY; WHITE MATTER; WHITE MATTER DISEASE;

BLOOD-BRAIN BARRIER; BRAIN; DEMYELINATING DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 20044372739     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.20336     Document Type: Conference Paper

References (53)

1. Rovaris M, Filippi M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol 1999;12:337-344.
2. Filippi M, Grossman RI. MRI techniques to monitor MS evolution: the present and the future. Neurology 2002;58:1147-1153.
3. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
4. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
5. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-1496
6. McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
7. Fazekas F, Barkhof F, Filippi M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999;53:448-456.
8. Frohman E, Goodin DS, Phillips JT, et al. The utility of MRI in suspected MS. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:602-611.
9. Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43:499-506.
10. Miller DH. MRI monitoring of MS in clinical trials. Clin Neurol Neurosurg 2002;104:236-243.
11. Schaefer PW. Applications of DWI in clinical neurology. J Neurol Sci 2001;186(Suppl 1):S25-S35.
12. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002;38:323-337.
13. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000;89:1371-1388.
14. Simon JH. Measures of gadolinium enhancement in multiple sclerosis. In: Cohen JA, Rudick RA, eds. Multiple sclerosis therapeutics, 2nd edition. London: Martin Dunitz; 2003. p 97-124.
15. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
16. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
17. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000;107:161-166.
18. Dousset V, Brochet B, Caille JM, Petry KG. Cell-specific imaging in pathologic conditions of the central nervous system, with special reference to multiple sclerosis. In: Filippi M, Comi G, editors. New frontiers of MRI-based techniques in multiple sclerosis. Milan: Springer-Verlag; 2003. p 5-10.
19. Tofts PS. Optimal detection of blood-brain barrier defects with Gd-DTPA MRI-the influences of delayed imaging and optimised repetition time. Magn Reson Imaging 1996;14:373-380.
20. Landis CS, Li X, Telang FW, et al. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 2000;44:563-574.
21. Mann CL, Davies MB, Boggild MD, et al. Glutathione S-transferase polymorphisms in MS: their relationship to disability. Neurology 2000;54:552-557.
22. Filippi M, Rocca MA, Rizzo G, et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology 1998;50:1289-1293.
23. Filippi M, Rovaris M, Capra R, et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999;67:386-389.
24. Rovaris M, Codella M, Moiola L, et al. Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. Neurology 2002;59:1429-1432.
25. Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DH. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler 2001;7:75-82.
26. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998;43:809-814.
27. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676-1695.
28. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology 2001;57:1253-1258.
29. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141-147.
30. McGowan JC. The physical basis of magnetization transfer imaging. Neurology 1999;3(Suppl 3):S3-S7.
31. Tortorella C, Viti B, Bozzali M. et al. A magnetization transfer histogram study of normal appearing brain tissue in multiple sclerosis. Neurology 2000;4:186-193.
32. Ge Y, Grossman RI, Udupa JK, et al. Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2001;22:470-475.
33. Cercignani M, Bozzali M, Iannucci G, Comi G, Filippi M. Magnetisation transfer ratio and mean diffusivity of normal-appearing white and gray matter from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:311-317.
34. Kalkers NF, Hintzen RQ, van Waesberghe JH, et al. Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. J Neurol Sci 2001;184:155-162.
35. Rovaris M, Agosta F, Sormani MP, et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 2003;126:2323-2332.
36. Basser PJ, Jones DK. Diffusion-tensor MRI: theory, experimental design and data analysis-a technical review. NMR Biomed 2002;15:456-467.
37. Filippi M, Inglese M. Overview of diffusion-weighted magnetic resonance studies in multiple sclerosis. J Neurol Sci 2001;186(Suppl 1):S37-S43.
38. Werring DJ, Clark CA, Barker GJ, Thompson AJ, Miller DH. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 1999;52:1626-1632.
39. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001;56:304-311.
40. Haselhorst R, Kappos L, Bilecen D, et al. Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging 2000;11:495-505.
41. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
42. Laule C, Vavasour IM, Moore GR, et al. Water content and myelin water fraction in multiple sclerosis. AT2 relaxation study. J Neurol 2004;251:284-293.
43. Arnold DL, Wolinsky JS, Matthews PM, Falini A. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64(Suppl 1):S94-S101.
44. De Stefane N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-727.
45. Filippi M. In-vivo tissue characterization of multiple sclerosis and other white matter diseases using magnetic resonance based techniques. J Neurol 2001;248:1019-1029.
46. Helms G. Volume correction for edema in single-volume proton MR spectroscopy of contrast-enhancing multiple sclerosis lesions. Magn Reson Med 2001;46:256-263
47. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-241.
48. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 2003;53:174-180.
49. Pike GB, De Stefane N, Narayanan S, Francis GS, Antel JP, Arnold DL. Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. AJNR Am J Neuroradiol 1999;20:829-837.
50. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-437.
51. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979;41:81-91.
52. De Stefane N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002;59:1565-1571.
53. Pelletier D, Nelson SJ, Oh J, et al. MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J Neurol Neurosurg Psychiatry 2003;74:950-952.